Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

NCT06383533 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Bile Duct Adenocarcinoma Non-Resectable
HER2 Gene Mutation

Interventions

DRUG: Disitamab Vedotin Plus Cadonilimab

Sponsor

Zhejiang Cancer Hospital